Bupivacaine-d9 Property

storage temp. 

Store at -20°C

solubility 

DMF: 30 mg/ml,DMSO: 25 mg/ml,Ethanol: 30 mg/ml

form 

A solid

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H315Causes skin irritation

H319Causes serious eye irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P271Use only outdoors or in a well-ventilated area.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P302+P352IF ON SKIN: wash with plenty of soap and water.

P304+P340IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

P321Specific treatment (see … on this label).

P330Rinse mouth.

P332+P313IF SKIN irritation occurs: Get medical advice/attention.

P337+P313IF eye irritation persists: Get medical advice/attention.

P501Dispose of contents/container to..…

Bupivacaine-d9 Chemical Properties,Usage,Production

Uses

(±)-Bupivacaine-d9 (butyl-d9) is an internal standard, useful for the detection of corticosteroids in human plasma.

Biological Activity

Bupivacaine-d9 is intended for use as an internal standard for the quantification of bupivacaine by GC- or LC-MS. Bupivacaine is a sodium channel blocker and local anesthetic.1,2 It inhibits sodium currents in rat dorsal horn neurons in a concentration-dependent manner and inhibits synaptic transmission in rat sympathetic ganglia, increasing the firing threshold when used at a concentration of 200 nM.3,4 Bupivacaine (10 μM) blocks cardiac sodium channels in a use-dependent manner and inhibits respiration in cardiac cell mitochondria when palmitoyl-carnitine or acetyl-carnitine are used as substrates (IC50s = 0.78 and 0.37 mM, respectively).1,5 It also reduces thermal hyperplasia in a rat model of sciatic ligation injury when 0.6 ml of a 0.5% solution is administered into the perinerve space, and the duration of this effect is extended by co-administration of the NMDA receptor antagonist MK-801 .2 Formulations containing bupivacaine have been used as local anesthetics for surgery, oral surgery, and dental procedures and for anesthetic purposes in research studies using animals.

References

1.Arlock, P.Actions of three local anaesthetics: lidocaine, bupivacaine and ropivacaine on guinea pig papillary muscle sodium channels (Vmax)Pharmacol. Toxicol.63(2)96-104(1988) 2.Mao, J., Price, D.D., Mayer, D.J., et al.Intrathecal MK-801 and local nerve anesthesia synergistically reduce nociceptive behaviors in rats with experimental peripheral mononeuropathyBrain Res.576(2)254-262(1992) 3.Olschewski, A., Hempelmann, G., Vogel, W., et al.Blockade of Na+ and K+ currents by local anesthetics in the dorsal horn neurons of the spinal cordAnesthesiology88(1)172-179(1998) 4.Tabatabai, M., and Booth, A.M.Mechanism of action of local anesthetics on synaptic transmission in the ratAnesth. Analg.71(2)149-157(1990) 5.Weinberg, G.L., Palmer, J.W., VadeBoncouer, T.R., et al.Bupivacaine inhibits acylcarnitine exchange in cardiac mitochondriaAnesthesiology92(2)523-528(2000)